See more : Allied Circuit Co., Ltd. (8155.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Vivani Medical, Inc. (VANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivani Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Guoco Group Limited (GULRY) Income Statement Analysis – Financial Results
- Hokuriku Electric Power Company (9505.T) Income Statement Analysis – Financial Results
- Furubayashi Shiko Co.,Ltd. (3944.T) Income Statement Analysis – Financial Results
- New Century AIM VCT Plc (NCA.L) Income Statement Analysis – Financial Results
- Paras Defence and Space Technologies Limited (PARAS.NS) Income Statement Analysis – Financial Results
Vivani Medical, Inc. (VANI)
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 6.90M | 7.96M | 3.99M | 8.95M | 3.40M | 1.56M | 1.37M |
| Cost of Revenue | 357.00K | 381.00K | 345.00K | 167.00K | 2.15M | 4.89M | 7.75M | 9.35M | 4.30M | 3.56M | 5.63M | 4.40M |
| Gross Profit | -357.00K | -381.00K | -345.00K | -167.00K | 1.23M | 2.01M | 211.00K | -5.36M | 4.65M | -160.28K | -4.06M | -3.03M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 36.31% | 29.12% | 2.65% | -134.60% | 51.93% | -4.72% | -259.72% | -221.58% |
| Research & Development | 16.97M | 14.17M | 11.00M | 6.87M | 16.50M | 10.21M | 7.99M | 5.35M | 3.04M | 5.04M | 3.25M | 3.05M |
| General & Administrative | 10.00M | 7.07M | 2.32M | 2.38M | 9.23M | 10.69M | 10.93M | 10.08M | 8.22M | 6.57M | 4.17M | 4.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.10M | 11.34M | 9.57M | 8.99M | 8.94M | 6.84M | 3.30M | 2.19M |
| SG&A | 10.00M | 7.07M | 2.32M | 2.38M | 15.33M | 26.63M | 23.56M | 21.77M | 20.67M | 13.41M | 7.47M | 6.22M |
| Other Expenses | 0.00 | 475.00K | -91.00K | -36.00K | 3.35M | 4.60M | 2.64M | -727.00K | -991.00K | 2.62M | 3.22M | 3.73M |
| Operating Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 31.82M | 36.83M | 28.92M | 27.85M | 24.70M | 21.07M | 13.93M | 12.99M |
| Cost & Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 33.98M | 41.72M | 36.67M | 37.20M | 29.00M | 24.63M | 19.56M | 17.39M |
| Interest Income | 0.00 | 0.00 | 0.00 | 16.00K | 362.00K | 86.00K | 93.00K | 31.00K | 2.00K | 9.11K | 7.45K | 7.51K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 7.03M | 5.01M | 267.03K |
| Depreciation & Amortization | 357.00K | 381.00K | 345.00K | 167.00K | 414.00K | 435.00K | 457.00K | 432.00K | 335.00K | 279.18K | 315.77K | 324.71K |
| EBITDA | -26.61M | -19.16M | -12.98M | -8.89M | -33.18M | -34.66M | -28.06M | -32.75M | -19.68M | -27.89M | -17.64M | -15.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -893.25% | -498.69% | -354.75% | -822.53% | -220.25% | -820.75% | -1,127.18% | -1,147.39% |
| Operating Income | -26.97M | -21.24M | -13.32M | -9.24M | -30.60M | -34.83M | -28.71M | -33.21M | -20.05M | -21.23M | -18.00M | -16.02M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -905.50% | -505.00% | -360.48% | -833.38% | -223.99% | -624.91% | -1,150.05% | -1,171.82% |
| Total Other Income/Expenses | 1.31M | 7.35M | 550.00K | -36.00K | -3.00M | -269.00K | 193.00K | 31.00K | 29.00K | -13.97M | -4.97M | -257.74K |
| Income Before Tax | -25.65M | -13.89M | -12.77M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| Income Tax Expense | 0.00 | -7.35M | -641.00K | 147.70K | 362.00K | 86.00K | 93.00K | 31.00K | 58.00K | -6.93M | 42.22K | 9.29K |
| Net Income | -25.65M | -6.54M | -12.13M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| EPS | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| EPS Diluted | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| Weighted Avg Shares Out | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
| Weighted Avg Shares Out (Dil) | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering neurostimulation to recover critical body function, has completed...
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-term therapeutic implants, announced today that Company CEO Adam Mendelsohn, Ph.D. has been invited to participate at the Healthcare...
Vivani Medical to Present at the ThinkEquity Investor Conference
EMERYVILLE, Calif.
Second Sight Medical Products (EYES) Stock: 1-For-3 Split Goes Into Effect
A 1-for-3 reverse split of Second Sight Medical Products (EYES) has gone into effect. These are the details.
Trading Penny Stocks? Top Stock Market News For February 8th, 2022
What you need to know about trading penny stocks on February 8th The post Trading Penny Stocks? Top Stock Market News For February 8th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical
Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction. Second Sight Medical develops implantable visual prosthetics.
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received...
Highest Volume Penny Stocks to Watch Today? Check These 4 Out
Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?
EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight
EYES stock is set for another day of double-digit gains after the European patent agency approved the company's application. The post EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight appeared first on InvestorPlace.
EYES Stock Increases Over 15% Pre-Market: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 15% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports